炎症性肠病症状量表在炎症性肠病中的应用

Inflammatory bowel disease symptoms inventory in inflammatory bowel disease

目的探讨炎症性肠病症状量表(IBDSI)评分在炎症性肠病(IBD)疾病评估中的临床价值。方法通过问卷方法,对2020年4月至2021年8月淮安市第一人民医院住院治疗的102例IBD患者的临床资料及IBDSI评分进行调查分析。对IBDSI评分与IBD疾病活动度指标和严重程度指标[所有患者的炎症指标,CD患者克罗恩病活动指数(CDAI),UC患者梅奥内镜评分(MES)及UC内窥镜下严重程度指数(UCEIS)]的相关性进行分析和评价。结果102例IBD患者的IBDSI总分(26.56±15.53)分。CD组、UC组的IBDSI总分及分量表评分差异无统计学意义(P>0.05)。CD组的腹部不适分量表与C反应蛋白呈正相关(r=0.35,P<0.05)。UC组的IBDSI总分与血沉降率呈正相关(r=0.49,P<0.05)。IBDSI总分与CD患者的CDAI、UC患者的MES及UCEIS分别呈正相关(P<0.05)。结论IBDSI评分是患者自我报告的症状评分,与IBD疾病活动度和严重程度相关。可用于我国IBD患者的疾病评估,且具有较高的临床应用价值。

Objective To explore the clinical value of the inflammatory bowel disease symptoms inventory(IBDSI)score in evaluation the severity of inflammatory bowel disease(IBD).Methods The clinical data and IBDSI scores of 102 IBD patients hospitalized in Huai an First People s Hospital from April 2020 to August 2021 were collected and analyzed by questionnaire,including IBDSI total scores and sub-item scores for 43 patients with Crohn s disease(CD group)and 59 patients with ulcerative colitis(UC group).The correlations between IBDSI score and IBD disease activity and severity indicators[inflammation index in all patients,Crohn's disease activity index(CDAI)in CD patients,Mayo endoscopic score(MES)and UC endoscopic severity index(UCEIS)in UC patients]were analyzed and evaluated.Results The IBDSI total score of 102 patients with IBD was(26.56±15.53).There were no significant differences in IBDSI total scores and sub-item scores between CD and UC groups(P>0.05).The abdominal discomfort sub-scale was positively correlated with C-reactive protein in CD group(r=0.35,P<0.05).The total IBDSI scores were positively correlated with erythrocyte sedimentation rate(ESR)in UC group(r=0.49,P<0.05).The IBDSI total scores were positively correlated with the scores of CDAI of CD patients,MES and UCEIS of UC patients(P<0.05),respectively.Conclusion The IBDSI score is a self-reported symptom score of patients and is related to the activity and severity of IBD disease.It has a high clinical application value in the evaluation of IBD patients in China.